漢田生技1294.TW Overview

1294 Key Information

1294 FAQ

• When is 1294's latest earnings report released?

  The most recent financial report for 漢田生技 (1294) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1294's short-term business performance and financial health. For the latest updates on 1294's earnings releases, visit this page regularly.

• Where does 1294 fall in the P/E River chart?

  According to historical valuation range analysis, 漢田生技 (1294)'s current price-to-earnings (P/E) ratio is 15.44, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

• What is the operating profit of 1294?

  According to the latest financial report, 漢田生技 (1294) reported an Operating Profit of 38.1M with an Operating Margin of 19.47% this period, representing a decline of 30.1% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

• How is 1294's revenue growth?

  In the latest financial report, 漢田生技 (1294) announced revenue of 195.67M, with a Year-Over-Year growth rate of -1.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

• How much cash does 1294 have?

  At the end of the period, 漢田生技 (1294) held Total Cash and Cash Equivalents of 216.25M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

• Does 1294 go with three margins increasing?

  In the latest report, 漢田生技 (1294) achieved the “three margins increasing” benchmark, with a gross margin of 35.14%%, operating margin of 19.47%%, and net margin of 15.77%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1294's profit trajectory and future growth potential.

• Is 1294's EPS continuing to grow?

  According to the past four quarterly reports, 漢田生技 (1294)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

• What is the FCF of 1294?

  漢田生技 (1294)'s Free Cash Flow (FCF) for the period is 46.24M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 118.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.